106 related articles for article (PubMed ID: 1825536)
1. Selective thromboxane synthase inhibition does not increase in vivo synthesis of prostacyclin in healthy humans.
Vesterqvist O; Gréen K; Henriksson P; Rasmanis G; Edhag O
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():165-8. PubMed ID: 1825536
[No Abstract] [Full Text] [Related]
2. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
[TBL] [Abstract][Full Text] [Related]
3. Thromboxane synthase inhibition: "endoperoxide shunt phenomenon" does not occur in healthy humans in vivo.
Henriksson P; Rasmanis G; Edhag O; Vesterqvist O; Gréen K
Prostaglandins; 1990 Jan; 39(1):99-107. PubMed ID: 2106716
[TBL] [Abstract][Full Text] [Related]
4. Selective and nonselective inhibition of thromboxane formation.
FitzGerald GA; Oates JA
Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554
[TBL] [Abstract][Full Text] [Related]
5. Different effects of thromboxane synthetase inhibition on PGI2 and PGE2 synthesis in human vascular tissue bathed in clotting blood.
Asai F; Schrör K
Prog Clin Biol Res; 1987; 242():259-64. PubMed ID: 3313413
[No Abstract] [Full Text] [Related]
6. Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses.
Hardee MM; Moore JN; Hardee GE
Res Vet Sci; 1986 Mar; 40(2):152-6. PubMed ID: 3517992
[TBL] [Abstract][Full Text] [Related]
7. Imidazo[1,5-a]pyridines: a new class of thromboxane A2 synthetase inhibitors.
Ford NF; Browne LJ; Campbell T; Gemenden C; Goldstein R; Gude C; Wasley JW
J Med Chem; 1985 Feb; 28(2):164-70. PubMed ID: 3918169
[TBL] [Abstract][Full Text] [Related]
8. Determination of the effects of inhibition of pulmonary thromboxane A2 synthase activity, in vivo and in vitro.
McNamara DB; Kerstein MD; Harrington JK; Bellan JA; Graybar GB; Hyman AL; Kadowitz PJ
Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():531-4. PubMed ID: 2526532
[No Abstract] [Full Text] [Related]
9. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
[TBL] [Abstract][Full Text] [Related]
10. [Chronic arterial occlusive diseases--drug therapy and thromboxane A2 synthetase inhibitor].
Yasuda K; Matsui Y; Goda T; Sakuma M; Go K
Nihon Rinsho; 1991 Sep; 49(9):2149-54. PubMed ID: 1960880
[No Abstract] [Full Text] [Related]
11. [Effect of cicletanine on prostacyclin generation in vivo].
Bourgain RH; Deby C; Andries R
Arch Mal Coeur Vaiss; 1989 Nov; 82 Spec No 4():33-6. PubMed ID: 2514665
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of arachidonate metabolism by selected compounds in vitro with particular emphasis on the thromboxane A2 synthase pathway.
Tobias LD; Hamilton JG
Adv Prostaglandin Thromboxane Res; 1980; 6():453-6. PubMed ID: 6770605
[No Abstract] [Full Text] [Related]
13. Biology and biochemistry of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():235-40. PubMed ID: 6221529
[No Abstract] [Full Text] [Related]
14. Synthesis of prostacyclin and thromboxane A2 by rat gastric mucosa. Comparison of 1,6-dimethyl-4-oxo-1,6,7,8,9,9a-hexahydro-4H-pyrido (1,1-a)-pyrimidine-3-carboxamide and cimetidine.
Rózsa I; Kapui Z; Szécsi T; Hermecz I; Blaskó G
Arzneimittelforschung; 1989 Jun; 39(6):686-9. PubMed ID: 2673252
[TBL] [Abstract][Full Text] [Related]
15. On the mechanism of thrombolytic action of thromboxane synthetase inhibitors.
Korbut R; Dembińska-Kieć A; Swies J; Zmuda A; Gryglewski RJ
Thromb Haemost; 1987 Oct; 58(3):827-30. PubMed ID: 3324381
[TBL] [Abstract][Full Text] [Related]
16. [Highlights of thromboxane synthetase inhibitor research].
Yu WG; Xu LN
Sheng Li Ke Xue Jin Zhan; 1990 Jul; 21(3):216-20. PubMed ID: 2244198
[No Abstract] [Full Text] [Related]
17. Prostacyclin, from discovery to clinical application.
Moncada S
J Pharmacol; 1985; 16 Suppl 1():71-88. PubMed ID: 3897717
[No Abstract] [Full Text] [Related]
18. A concept for the mechanism of prostacyclin and thromboxane A2 biosynthesis.
Ullrich V; Hecker M
Adv Prostaglandin Thromboxane Leukot Res; 1990; 20():95-101. PubMed ID: 2144703
[No Abstract] [Full Text] [Related]
19. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
Gresele P; Blockmans D; Deckmyn H; Vermylen J
J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of thromboxane synthetase by dazoxiben increases prostacyclin production by leukocytes in angina patients and healthy volunteers.
Parry MJ; Randall MJ; Tyler HM; Myhre E; Dale J; Thaulow E
Lancet; 1982 Jul; 2(8290):164. PubMed ID: 6123880
[No Abstract] [Full Text] [Related]
[Next] [New Search]
